Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Guardant Health (GH) PT Lowered to $130 at Stifel
February 24, 2022 6:57 AM ESTStifel analyst Daniel Arias lowered the price target on Guardant Health (NASDAQ: GH) to $130.00 (from $160.00) while maintaining a Buy rating.
The analyst commented, "GH finished the year with a good beat and an initial 2022 outlook that includes solid clinical volume growth expectations... More
Guardant Health (GH) PT Lowered to $110 at Cowen
February 24, 2022 6:42 AM ESTCowen analyst Max Masucci lowered the price target on Guardant Health (NASDAQ: GH) to $110.00 (from $170.00) while maintaining an Outperform rating.
The analyst commented, "With the ECLIPSE trial readout expected in mid-2022, GH is approaching another landmark event for the field of cancer... More
Guardant Health (GH) Tops Q4 EPS by 46c
February 23, 2022 4:15 PM ESTGuardant Health (NASDAQ: GH) reported Q4 EPS of ($0.69), $0.46 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $108 million versus the consensus estimate of $98.61 million.
GUIDANCE:
Guardant Health sees FY2022 revenue of $460-470 million, versus the consensus of... More
